Breakthrough Findings from Cambridge Researchers on Testosterone and Heart Risk
Researchers at the University of Cambridge have uncovered compelling evidence linking higher circulating testosterone levels to an elevated risk of coronary artery disease (CAD) in men. This study, published in advance in the Journal of Clinical Endocrinology & Metabolism on October 24, 2025, utilized advanced genetic analysis to establish a causal relationship, challenging some prior assumptions about hormone levels and cardiovascular health.
The findings come at a time when testosterone supplementation is increasingly popular, driven by awareness of hypogonadism—low testosterone production—and trends in fitness and anti-aging markets. Emily Morbey, a PhD student at the MRC Epidemiology Unit, University of Cambridge, noted the rising use among younger men influenced by social media and marketing. This research prompts a reevaluation of the benefits versus potential dangers, particularly for non-medical use.
Coronary artery disease, often abbreviated as CAD, occurs when plaque builds up in the arteries supplying the heart, narrowing them and reducing blood flow. This can lead to angina, heart attacks, or heart failure. In the UK, heart and circulatory diseases affect millions, making such discoveries vital for public health strategies.
Unpacking Coronary Artery Disease: Definition, Symptoms, and Prevalence
Coronary artery disease (CAD) is the most common type of cardiovascular disease, responsible for a significant portion of deaths and hospital admissions. It develops gradually as fatty deposits, cholesterol, calcium, and other substances form plaques in the coronary arteries. These plaques can rupture, causing blood clots that block blood flow entirely.
Symptoms include chest pain (angina), shortness of breath, fatigue, and pain in the arms, neck, jaw, or back, often triggered by exertion. Risk factors encompass high blood pressure, smoking, diabetes, high cholesterol, obesity, and inactivity. According to British Heart Foundation (BHF) data from 2025, approximately 2.3 million people in the UK live with coronary heart disease (CHD), which encompasses CAD, with about 1.5 million being men.
Recent trends show concerning rises in cardiovascular deaths among under-65s after decades of decline, highlighting the urgency of identifying modifiable risks like hormone influences.
- Chest pain or discomfort, especially during physical activity
- Shortness of breath
- Heart palpitations or irregular heartbeat
- Sudden severe chest pain signaling a heart attack
Early detection through lifestyle checks and screenings can prevent progression, emphasizing the role of research like Cambridge's in pinpointing unexpected contributors.
Testosterone Fundamentals: Normal Levels, Functions, and Imbalances
Testosterone, the primary male sex hormone produced mainly in the testes, plays crucial roles in muscle mass, bone density, red blood cell production, sex drive, and sperm production. In adult men, normal total testosterone levels range from 8.6 to 29 nmol/L (249-835 ng/dL), measured via blood tests, ideally in the morning when levels peak.
Hypogonadism occurs when levels fall below 8 nmol/L chronically, leading to fatigue, reduced libido, erectile dysfunction, depression, and loss of muscle mass. Conversely, supraphysiological levels—above the upper normal range—can arise from supplementation or anabolic steroid use.
The Cambridge study focused on genetically predicted circulating testosterone, using lifelong exposure estimates rather than short-term measurements, providing robust causal insights.
The Science Behind the Study: Mendelian Randomization and UK Biobank Power
Mendelian randomization (MR) is a genetic epidemiology technique that leverages randomly inherited genetic variants as natural proxies for modifiable exposures, mimicking randomized controlled trials. It minimizes confounding by reverse causation or lifestyle factors since genes are fixed at conception.
The researchers identified genetic instruments—single nucleotide polymorphisms (SNPs)—strongly associated with testosterone levels from genome-wide association studies (GWAS). They applied two-sample MR using data from over 400,000 UK Biobank participants for testosterone prediction and CARDIoGRAMplusC4D consortium (>1 million individuals) for CAD outcomes.
This large-scale approach confirmed no pleiotropy (variants affecting CAD via other paths), strengthening causality claims. Survival analyses further linked higher testosterone to increased CAD mortality risk.
Core Results: 17% Higher CAD Odds and Blood Pressure Mediation
The pivotal finding: genetically higher testosterone conferred a 17% increased odds of CAD in men (odds ratio [OR] 1.17, 95% confidence interval [CI] 1.07-1.27, P=3.32×10^{-4}). This translates to a lifetime risk rise from 7.3% to 8.5% for those at the higher end.
The effect was mediated partly by elevated blood pressure, a known CAD driver. No significant CAD association emerged in women, underscoring sex-specific impacts.
| Outcome | Men OR (95% CI) | P-value |
|---|---|---|
| Coronary Artery Disease | 1.17 (1.07-1.27) | 3.32×10^{-4} |
| Hypertension (mediation) | Positive association | <0.05 |
| CAD in Women | No significant link | N/A |
These robust statistics highlight testosterone's potential prothrombotic and vasculopathic effects.
Navigating Conflicting Evidence: Low vs High Testosterone Studies
Prior observational studies often linked low endogenous testosterone to higher CVD mortality, sparking TRT (testosterone replacement therapy) interest for hypogonadal men. However, RCTs like TRAVERSE (2023) found no short-term CV risk increase with TRT in middle-aged/older men.
The Cambridge MR study shifts focus to high levels, suggesting U-shaped risk: both very low and very high testosterone may harm. Anabolic abuse studies corroborate excess risks like erythrocytosis and hypertension.
This reconciles discrepancies, as TRT typically normalizes rather than elevates levels medically.
Implications for TRT and Supplementation in the UK ContextView the full study
Testosterone replacement therapy (TRT) is prescribed for confirmed hypogonadism after two low morning tests and symptom evaluation. UK guidelines from NICE and the British Society for Sexual Medicine emphasize monitoring prostate, hematocrit, and lipids, but lack specific CV warnings unlike US FDA black-box alerts.
Prof. Ken Ong advocates consistent UK warnings post this study. For performance enhancement, risks likely outweigh benefits. Patients should consult endocrinologists; explore career advice for medical researchers delving into such fields.
UK CAD Landscape: Sobering Statistics and Trends
The British Heart Foundation's 2025 compendium reveals 7.6 million UK adults with heart/circulatory diseases. CHD causes ~20% male deaths, with 85,000 CVD deaths yearly. Men face higher premature CAD risk before 65.
Post-COVID rises in young adult CV deaths underscore prevention needs. Integrating hormone screening could refine risk models.BHF Statistics
- 1 in 4 UK male deaths CVD-related
- 2.3m CHD cases (1.5m men)
- Rising under-65 mortality
Voices from the Experts: Quotes and Perspectives
"Our work indicates that high levels of testosterone in the blood increase the risk of coronary artery disease, which in turn can put people at risk of heart attack and heart failure." – Emily Morbey.
"In the UK, there is no national guidance on the potential cardiovascular risk of high levels of testosterone. Our results suggest there's a need for more consistent warnings." – Prof. Ken Ong.
Stakeholders like endocrinologists urge balanced views: TRT safe when indicated, but vigilance essential.
Actionable Strategies: Maintaining Heart-Healthy Hormone Balance
Beyond genetics, lifestyle modulates risks. Regular exercise, Mediterranean diet, stress management, and avoiding smoking optimize testosterone naturally without excess.
- Aim 150min moderate cardio weekly
- Monitor BP and cholesterol annually
- Limit alcohol; prioritize sleep
- Consult GP before supplements
For academics researching CV health, opportunities abound in research jobs at institutions like Cambridge.
Spotlight on University of Cambridge's MRC Epidemiology Unit
The MRC Epidemiology Unit at Cambridge excels in genetic-environmental interactions for NCDs like diabetes and CVD. Funded by Medical Research Council, it leverages UK Biobank for groundbreaking MR studies, positioning Cambridge as a global leader.
Aspiring researchers can pursue PhDs or postdocs; check postdoc positions or research assistant jobs to contribute to such vital work.
Looking Ahead: Future Research and Policy Shifts
Ongoing trials will clarify long-term TRT effects in high-risk groups. Policy may evolve with MHRA reviews incorporating this data. Personalized medicine via genetics promises refined risk stratification.
Cambridge's work exemplifies higher education's role in translating science to society, fostering healthier futures.
Balancing Hormone Optimization with Cardiovascular Vigilance
This Cambridge study illuminates high testosterone's CAD risks, urging caution in supplementation while affirming TRT's place for hypogonadism. Men prioritizing health should seek evidence-based advice, monitor biomarkers, and embrace holistic wellness.
Explore rate my professor for top CV experts, higher ed jobs in research, career advice, or university jobs. Share insights below and stay informed.